HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.
BMC Cancer. 2022 Jul 6;22(1):738. doi: 10.1186/s12885-022-09840-6.
BMC Cancer. 2022.
PMID: 35794593
Free PMC article.